Tentative Jan. 2024 Preferred Drug List Review Schedule Available
Published on
The tentative preferred drug list review schedule for the Jan. 26, 2024, Texas Drug Utilization Review Board is available.
Drug Classes
- Acne Agents, oral
- Acne Agents, topical
- Analgesics, Narcotics Long
- Analgesics, Narcotics Short
- Angiotensin Modulator Combinations
- Angiotensin Modulators
- Antihypertensives, Sympatholytic
- Antimigraine Agents, other
- Antimigraine Agents, triptans
- Antiparkinsons Agents
- Bladder Relaxant Preparations
- Glucagon Agents
- H. Pylori Treatment
- Intranasal Rhinitis Agents
- Movement Disorders
- Neuropathic Pain
- Oncology, Oral - Breast
- Oncology, Oral - Hematologic
- Oncology, Oral - Lung
- Oncology, Oral - Other
- Oncology, Oral - Prostate
- Oncology, Oral - Renal Cell
- Oncology, Oral - Skin
- PAH Agents, Oral and Inhaled
- Pancreatic Enzymes
- Phosphate Binders
- Platelet Aggregation Inhibitors
- Potassium Binders
- Progestins for Cachexia
- Proton Pump Inhibitors
- Smoking Cessation
- Stimulants and Related Agents
Single Drugs / PDL Classes
- Rykindo (intramuscular) / Antipsychotics
- Adalimumab-Adbm Kit (Injection) (CF) 50 mg/ml / Cytokine and CAM Antagonists
- Adalimumab-Adbm Pen Kit (Injection) (CF) 50 mg/ml / Cytokine and CAM Antagonists
- Entyvio Pen (subcutane.) / Cytokine and CAM Antagonists
- Jesduvroq Tablet (oral) / Erythropoiesis Stimulating Proteins
- Airsupra Hfa (inhalation) / Glucocorticoids, Inhaled
- Ojjaara (oral) / Oncology, Oral - Hematologic
- Akeega (oral) / Oncology, Oral - Prostate
- Narcan Spray OTC (nasal) / Opiate Dependence Treatments
- Motpoly XR (oral) / Anticonvulsants